Schedule of Our Chief Officer Decision Maker Evaluates Segment Performance |
Our chief operating officer- decision maker evaluates segment performance to the GAAP measure of gross profit.
| |
| Three
Months | |
| |
| Ended
| | |
| April
30, | |
| |
| 2025 | | |
| 2024 | |
| |
| | | |
| | |
Net sales | |
| | | |
| | |
Pocono
Pharmaceuticals | |
$ | 667,432 | | |
$ | 408,532 | |
4P Therapeutics | |
| - | | |
| - | |
| |
| 667,432 | | |
| 408,532 | |
Gross profit | |
| | | |
| | |
Pocono Pharmaceuticals | |
| 251,981 | | |
| 164,786 | |
4P Therapeutics | |
| - | | |
| - | |
| |
| 251,981 | | |
| 164,786 | |
Operating expenses | |
| | | |
| | |
Selling,
general and administrative-Pocono Pharmaceuticals | |
| 151,528 | | |
| 154,394 | |
Selling,
general and administrative-4P Therapeutics | |
| 19,999 | | |
| 24,354 | |
Selling,
general and administrative-Corporate | |
| 810,525 | | |
| 900,980 | |
Research
and development-4P Therapeutics | |
| 683,426 | | |
| 974,535 | |
| |
| 1,665,478 | | |
| 2,054,263 | |
Depreciation and Amortization | |
| | | |
| | |
Pocono Pharmaceuticals | |
$ | 48,213 | | |
$ | 56,823 | |
Corporate | |
| - | | |
| 3,011 | |
4P Therapeutics | |
| 9,267 | | |
| 9,267 | |
| |
$ | 57,480 | | |
$ | 69,101 | |
|
Our chief officer decision maker evaluates segment performance to the GAAP measure
of gross profit.
| |
Years Ending January 31, | |
| |
2025 | | |
2024 | |
Net sales | |
| | |
| |
Pocono Pharmaceuticals | |
$ | 2,139,537 | | |
$ | 1,920,280 | |
4P Therapeutics | |
| - | | |
| 165,034 | |
| |
| 2,139,537 | | |
| 2,085,314 | |
Gross profit | |
| | | |
| | |
Pocono Pharmaceuticals | |
| 743,317 | | |
| 744,391 | |
4P Therapeutics | |
| - | | |
| 117,714 | |
| |
| 743,317 | | |
| 862,105 | |
Operating expenses | |
| | | |
| | |
Selling, general and administrative-Pocono Pharmaceuticals | |
| 661,805 | | |
| 606,275 | |
Selling, general and administrative-4P Therapeutics | |
| 136,294 | | |
| 236,953 | |
Selling, general and administrative-Corporate | |
| 3,515,711 | | |
| 2,930,378 | |
Goodwill and intangibles impairment | |
| 3,595,216 | | |
| - | |
Research and development-4P Therapeutics | |
| 3,119,134 | | |
| 1,960,425 | |
| |
| 11,028,160 | | |
| 5,734,031 | |
Depreciation and Amortization | |
| | | |
| | |
Pocono Pharmaceuticals | |
$ | 235,941 | | |
$ | 222,159 | |
Corporate | |
| 12,043 | | |
| 13,986 | |
4P Therapeutics | |
| 37,070 | | |
| 51,577 | |
| |
$ | 285,054 | | |
$ | 287,722 | |
|
Schedule of Net Sales and Property and Equipment |
The following table presents information
about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.
| |
Three Months | |
| |
Ended | |
| |
April 30, | |
| |
2025 | | |
2024 | |
Net sales | |
| | | |
| | |
United States | |
$ | 667,432 | | |
$ | 408,532 | |
Outside the United States | |
| - | | |
| - | |
| |
$ | 667,432 | | |
$ | 408,532 | |
| |
| April
30, | | |
| January
31, | |
| |
| 2025 | | |
| 2025 | |
Property and equipment, net of accumulated depreciation | |
| | | |
| | |
United States | |
$ | 658,073 | | |
$ | 695,063 | |
Outside the United States | |
| - | | |
| - | |
| |
$ | 658,073 | | |
$ | 695,063 | |
Assets | |
| | | |
| | |
Corporate | |
$ | 2,869,688 | | |
$ | 4,205,577 | |
Pocono Pharmaceuticals | |
| 1,427,893 | | |
| 1,404,285 | |
4P Therapeutics | |
| 1,854,600 | | |
| 1,859,793 | |
| |
$ | 6,152,181 | | |
$ | 7,469,655 | |
|
The following table presents information
about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.
| |
Years Ending January 31, | |
| |
2025 | | |
2024 | |
Net sales | |
| | |
| |
United States | |
$ | 2,139,537 | | |
$ | 2,085,314 | |
Outside the United States | |
| - | | |
| - | |
| |
$ | 2,139,537 | | |
$ | 2,085,314 | |
| |
January 31, | | |
January 31, | |
| |
2025 | | |
2024 | |
Property and equipment, net of accumulated depreciation | |
| | |
| |
United States | |
$ | 695,063 | | |
$ | 774,924 | |
Outside the United States | |
| - | | |
| - | |
| |
$ | 695,063 | | |
$ | 774,924 | |
Assets | |
| | | |
| | |
Corporate | |
$ | 4,205,577 | | |
$ | 339,552 | |
Pocono Pharmaceuticals | |
| 1,404,585 | | |
| 5,079,293 | |
4P Therapeutics | |
| 1,859,793 | | |
| 2,098,309 | |
| |
$ | 7,469,955 | | |
$ | 7,517,154 | |
|